Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer

Gaetano Aurilio; Maria Teresa Sandri; Giancarlo Pruneri; Laura Zorzino; Edoardo Botteri; Elisabetta Munzone; Laura Adamoli; Giuseppina Facchi; Daniela Cullurà; Elena Verri; Maria Cossu Rocca; Stefano Zurrida; Roberto Iacovelli; Franco Nolè

doi:10.2217/fon-2016-0081

Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer

Gaetano Aurilio, Maria Teresa Sandri, Giancarlo Pruneri, Laura Zorzino, Edoardo Botteri, Elisabetta Munzone, Laura Adamoli, Giuseppina Facchi, Daniela Cullurà, Elena Verri, Maria Cossu Rocca, Stefano Zurrida, Roberto Iacovelli, Franco Nolè

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur^® Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.

Original language	English
Pages (from-to)	2001-2008
Number of pages	8
Journal	Future Oncology
Volume	12
Issue number	17
DOIs	https://doi.org/10.2217/fon-2016-0081
Publication status	Published - Sep 1 2016

Keywords

HER2 CTC status
metastatic breast cancer
serum HER2 ECD levels
survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2016-0081

Cite this

Aurilio, G., Sandri, M. T., Pruneri, G., Zorzino, L., Botteri, E., Munzone, E., Adamoli, L., Facchi, G., Cullurà, D., Verri, E., Rocca, M. C., Zurrida, S., Iacovelli, R., & Nolè, F. (2016). Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncology, 12(17), 2001-2008. https://doi.org/10.2217/fon-2016-0081

Aurilio, G , Sandri, MT , Pruneri, G , Zorzino, L, Botteri, E, Munzone, E , Adamoli, L, Facchi, G, Cullurà, D , Verri, E , Rocca, MC, Zurrida, S, Iacovelli, R & Nolè, F 2016, 'Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer', Future Oncology, vol. 12, no. 17, pp. 2001-2008. https://doi.org/10.2217/fon-2016-0081

@article{9031b5d3b0064e3aa2fe72f7242c550f,

title = "Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer",

abstract = "Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur{\textregistered} Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.",

keywords = "HER2 CTC status, metastatic breast cancer, serum HER2 ECD levels, survival",

author = "Gaetano Aurilio and Sandri, {Maria Teresa} and Giancarlo Pruneri and Laura Zorzino and Edoardo Botteri and Elisabetta Munzone and Laura Adamoli and Giuseppina Facchi and Daniela Cullur{\`a} and Elena Verri and Rocca, {Maria Cossu} and Stefano Zurrida and Roberto Iacovelli and Franco Nol{\`e}",

year = "2016",

month = sep,

day = "1",

doi = "10.2217/fon-2016-0081",

language = "English",

volume = "12",

pages = "2001--2008",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "17",

}

TY - JOUR

T1 - Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer

AU - Aurilio, Gaetano

AU - Sandri, Maria Teresa

AU - Pruneri, Giancarlo

AU - Zorzino, Laura

AU - Botteri, Edoardo

AU - Munzone, Elisabetta

AU - Adamoli, Laura

AU - Facchi, Giuseppina

AU - Cullurà, Daniela

AU - Verri, Elena

AU - Rocca, Maria Cossu

AU - Zurrida, Stefano

AU - Iacovelli, Roberto

AU - Nolè, Franco

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur® Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.

AB - Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur® Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.

KW - HER2 CTC status

KW - metastatic breast cancer

KW - serum HER2 ECD levels

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84983371797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983371797&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0081

DO - 10.2217/fon-2016-0081

M3 - Article

AN - SCOPUS:84983371797

VL - 12

SP - 2001

EP - 2008

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 17

ER -

Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this